

Supplementary Table 1. Survival of humanized mice infected with B95-8/fLuc and M81/fLuc (survival days post-infection; 56 days was the terminal endpoint; early deaths are underlined). CTR – control group, LD – low dose, HD – high dose of Pembrolizumab.

| Survival | | | Survival | | |
|----------------|----------|---------------------|--------------|----------|---------------------|
| EBV-B95-8/fLuc | | | EBV-M81/fLuc | | |
| Group | Mouse ID | Days post-infection | Group | Mouse ID | Days post-infection |
| CTR (PBS) | 747 | 56 | CTR (PBS) | 114 | 56 |
| CTR (PBS) | 748 | 56 | CTR (PBS) | 122 | 56 |
| CTR (PBS) | 1750 | <u>42</u> | CTR (PBS) | 145 | 56 |
| CTR (PBS) | 1751 | 56 | CTR (KIOVIG) | 119 | 56 |
| Pembro (LD) | 626 | 56 | CTR (KIOVIG) | 120 | 56 |
| Pembro (LD) | 632 | 56 | CTR (KIOVIG) | 121 | 56 |
| Pembro (LD) | 1752 | 56 | Pembro (LD) | 125 | 56 |
| Pembro (LD) | 1767 | 56 | Pembro (LD) | 126 | 56 |
| Pembro (LD) | 1768 | 56 | Pembro (LD) | 144 | <u>53</u> |
| Pembro (HD) | 625 | 56 | Pembro (LD) | 793 | <u>47</u> |
| Pembro (HD) | 631 | 56 | Pembro (LD) | 794 | <u>42</u> |
| Pembro (HD) | 746 | 56 | Pembro (LD) | 795 | <u>53</u> |
| Pembro (HD) | 1769 | 56 | Pembro (HD) | 105 | <u>42</u> |
| Pembro (HD) | 1770 | 56 | Pembro (HD) | 106 | <u>33</u> |
| Pembro (HD) | 1771 | 56 | Pembro (HD) | 107 | <u>28</u> |
| | | | Pembro (HD) | 796 | <u>47</u> |
| | | | Pembro (HD) | 886 | <u>51</u> |
| | | | Pembro (HD) | 887 | <u>42</u> |